» Authors » Guo-Hua Bi

Guo-Hua Bi

Explore the profile of Guo-Hua Bi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 62
Citations 1573
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Shen H, Ma Z, Hans E, Duan Y, Bi G, Chae Y, et al.
eNeuro . 2025 Mar; 12(3). PMID: 40032530
Impulsivity is often considered a risk factor for drug addiction; however, not all evidence supports this view. In the present study, we used a food reward delay-discounting task (DDT) to...
2.
Xi Z, Soler-Cedeno O, Galaj E, Klein B, Cao J, Bi G, et al.
Res Sq . 2024 Nov; PMID: 39606448
Cocaine use disorder (CUD) is a severe public health problem, and currently, there is no FDA-approved medication for its treatment. Atypical dopamine (DA) transporter (DAT) inhibitors display low addictive liability...
3.
Shen H, Ma Z, Hans E, Duan Y, Bi G, Chae Y, et al.
Neuropharmacology . 2024 Jun; 257:110051. PMID: 38917939
Impulsive decision-making has been linked to impulse control disorders and substance use disorders. However, the neural mechanisms underlying impulsive choice are not fully understood. While previous PET imaging and autoradiography...
4.
Xi Z, Bocarsly M, Galaj E, Hempel B, Teresi C, Shaw M, et al.
Biol Psychiatry . 2024 Jun; 96(9):752-765. PMID: 38838841
Background: Past research has illuminated pivotal roles of dopamine D receptors (DR) in the rewarding effects of cocaine and opioids. However, the cellular and neural circuit mechanisms that underlie these...
5.
Galaj E, Bi G, Xi Z
Neuropharmacology . 2024 Apr; 252:109947. PMID: 38631564
A growing body of research indicates that β-caryophyllene (BCP), a constituent present in a large number of plants, possesses significant therapeutic properties against CNS disorders, including alcohol and psychostimulant use...
6.
Soler-Cedeno O, Alton H, Bi G, Linz E, Ji L, Makriyannis A, et al.
Neuropsychopharmacology . 2024 Apr; 49(11):1678-1688. PMID: 38600154
Preclinical research has demonstrated the efficacy of CB1 receptor (CB1R) antagonists in reducing drug-taking behavior. However, clinical trials with rimonabant, a CB1R antagonist with inverse agonist profile, failed due to...
7.
He Y, Shen H, Bi G, Zhang H, Soler-Cedeno O, Alton H, et al.
Transl Psychiatry . 2024 Feb; 14(1):101. PMID: 38374108
G protein-coupled receptor 55 (GPR55) has been thought to be a putative cannabinoid receptor. However, little is known about its functional role in cannabinoid action and substance use disorders. Here...
8.
Xi Z, He Y, Shen H, Bi G, Zhang H, Soler-Cedeno O, et al.
Res Sq . 2023 Oct; PMID: 37886574
Cannabis legalization continues to progress in the USA for medical and recreational purposes. G protein-coupled receptor 55 (GPR55) is a putative "CB3" receptor. However, its functional role in cannabinoid action...
9.
Hempel B, Crissman M, Pari S, Klein B, Bi G, Alton H, et al.
Mol Psychiatry . 2023 Jul; 28(10):4203-4214. PMID: 37479780
Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear receptors that regulate gene expression. Δ-tetrahydrocannabinol (Δ-THC) is a PPARγ agonist and some endocannabinoids are natural activators of PPARα and PPARγ....
10.
Xi Z, Hempel B, Crissman M, Pari S, Klein B, Bi G, et al.
Res Sq . 2023 Mar; PMID: 36909477
Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear receptors that regulate gene expression. Δ -tetrahydrocannabinol (Δ -THC) is a PPARg agonist and some endocannabinoids are natural activators of PPAR...